AMAG PHARMACEUTICALS, INC. - FORM 10-K - EX-23.1 - EXHIBIT 23.1 - February 28, 2018

Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - AMAG PHARMACEUTICALS, INC.ex322.htm
EX-32.1 - EXHIBIT 32.1 - AMAG PHARMACEUTICALS, INC.ex321.htm
EX-31.2 - EXHIBIT 31.2 - AMAG PHARMACEUTICALS, INC.ex312.htm
EX-31.1 - EXHIBIT 31.1 - AMAG PHARMACEUTICALS, INC.ex311.htm
EX-21.1 - EXHIBIT 21.1 - AMAG PHARMACEUTICALS, INC.ex211.htm
EX-10.13 - EXHIBIT 10.13 - AMAG PHARMACEUTICALS, INC.ex1013.htm
EX-10.12 - EXHIBIT 10.12 - AMAG PHARMACEUTICALS, INC.ex1012.htm
EX-10.10 - EXHIBIT 10.10 - AMAG PHARMACEUTICALS, INC.ex1010.htm
EX-10.9 - EXHIBIT 10.9 - AMAG PHARMACEUTICALS, INC.ex109.htm
EX-10.8 - EXHIBIT 10.8 - AMAG PHARMACEUTICALS, INC.ex108.htm
EX-10.7 - EXHIBIT 10.7 - AMAG PHARMACEUTICALS, INC.ex107.htm
EX-10.6 - EXHIBIT 10.6 - AMAG PHARMACEUTICALS, INC.ex106.htm
10-K - 10-K - AMAG PHARMACEUTICALS, INC.a201710-k.htm
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Forms S‑3 (File Nos. 333‑202009 and 333-202252) and Forms S‑8 (File Nos. 333‑131656, 333‑148682, 333‑159938, 333‑168786, 333-182821, 333‑190435, 333‑197873, 333-203924, 333-211277 and 333-218911) of AMAG Pharmaceuticals, Inc. of our report dated February 28, 2018 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.

/s/ PricewaterhouseCoopers LLP
 
Boston, Massachusetts
 
February 28, 2018
 



AMAG PHARMACEUTICALS, INC. Reports